Safety and Pharmacokinetics of Ppi-461, a Potent New Hepatitis C Virus (Hcv) Ns5a Inhibitor with Pan-Genotype Activity
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2010
At a glance
- Drugs PPI 461 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- 27 Oct 2010 Results from this trial will be presented at the American Association for the Study of Liver Diseases (AASLD) according to a Presidio Pharmaceuticals media release.
- 14 Jul 2010 Status changed from recruiting to completed, according to a Presidio Pharmaceuticals media release.
- 14 Jul 2010 Results reported in a Presidio Pharmaceuticals media release.